within Pharmacolibrary.Drugs.ATC.S;

model S01AA13
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.6666666666666668e-07,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01AA13</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fusidic acid is an antibiotic of the steroid class used to treat bacterial infections, particularly those caused by staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA). It is mainly used for skin and eye infections and is formulated topically and systemically. For ocular use (ATC S01AA13), it is available as an ophthalmic gel or drops. Fusidic acid is approved and used in many countries today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for topical (ocular) administration in adults. No published compartmental pharmacokinetics models specific to ocular (ATC S01AA13) administration of fusidic acid were found. Most published PK data are from oral or intravenous use or systemic exposure studies.</p><h4>References</h4><ol><li><p>Turnidge, J (1999). Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. <i>International journal of antimicrobial agents</i> 12 Suppl 2 S23–S34. DOI:<a href=&quot;https://doi.org/10.1016/s0924-8579(98)00071-5&quot;>10.1016/s0924-8579(98)00071-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10528784/&quot;>https://pubmed.ncbi.nlm.nih.gov/10528784</a></p></li><li><p>Bonamonte, D, et al., &amp; Patrizi, A (2014). Fusidic acid in skin infections and infected atopic eczema. <i>Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia</i> 149(4) 453–459. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25068235/&quot;>https://pubmed.ncbi.nlm.nih.gov/25068235</a></p></li><li><p>Doughty, MJ, &amp; Dutton, GN (2006). Fusidic acid viscous eyedrops--an evaluation of pharmacodynamics, pharmacokinetics and clinical use for UK optometrists. <i>Ophthalmic &amp; physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)</i> 26(4) 343–361. DOI:<a href=&quot;https://doi.org/10.1111/j.1475-1313.2006.00416.x&quot;>10.1111/j.1475-1313.2006.00416.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16792734/&quot;>https://pubmed.ncbi.nlm.nih.gov/16792734</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01AA13;
